<DOC>
	<DOCNO>NCT02521753</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) prevalent endocrine disorder reproductive age woman . PCOS usually characterize excessive androgen production , menstrual irregularity , polycystic ovary . Women PCOS often obese vary degree insulin resistance ( IR ) . Weight reduction constitute initial treatment patient . Metformin proven useful IR frequently use PCOS . However metformin use may accompany gastrointestinal discomfort , high abandon rate . Other therapeutic alternative magnesium polyunsaturated fatty acid use IR state may useful PCOS . The aim study asses efficacy alternative obese PCOS patient .</brief_summary>
	<brief_title>Omega 3 Polyunsaturated Fatty Acids ( PUFA ) Magnesium Obese Polycystic Ovary Syndrome Patients</brief_title>
	<detailed_description>Polycystic Ovary Syndrome ( PCOS )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Polycystic Ovary Syndrome accord Rotterdam criterion , BMI â‰¥ 27 Kg/m2 Type 2 diabetes mellitus , treatment polycystic ovary syndrome feature</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Metformin</keyword>
	<keyword>Magnesium</keyword>
	<keyword>Polyunsaturated fatty acid</keyword>
</DOC>